SLC5A2 and diabetic kidney disease: This milestone is noteworthy for both the nephrology community and patients with diabetes-related kidney and/or cardiovascular diseases, as SGLT2 inhibitors emerge as the first novel treatment option in the last 2 decades to effectively combat the progression of diabetic kidney disease.